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Objectives. This study sought to investigate the contribution of
ticlopidine to the inhibition of platelet activation after coronary
stent placement.
Background. After coronary stenting, antiplatelet therapy with
aspirin and ticlopidine improves stent patency compared with
anticoagulation. However, the specific role of ticlopidine has not
been elucidated.
Methods. After successful coronary stent placement, we ran-
domized 22 patients to receive ticlopidine and aspirin (ticlopidine
group) and 25 to receive aspirin alone (aspirin group). Surface
expression on platelets of the activated fibrinogen receptor and of
P-selectin was assessed by flow cytometry.
Results. In the aspirin group the percent of platelets with
activated fibrinogen receptors increased between days 1 and 5
(p 5 0.001), whereas there were no substantial changes in the
ticlopidine group. The percent of P-selectin–positive platelets
did not change significantly in the aspirin group but decreased in
the ticlopidine group (p 5 0.019). At day 5 after the intervention,
the percent of platelets with activated fibrinogen receptors in the
ticlopidine group was significantly lower (median [interquartile
range]: 8.5 [3.1 to 17.8] vs. 18.1 [8.5 to 35.5], p 5 0.025), and there
was a trend to fewer P-selectin–positive platelets than in the
aspirin group (5.8 [3.4 to 9.5] vs. 8.8 [4.0 to 15.8], p 5 0.073).
Conclusions. Combined antiplatelet therapy with ticlopidine
plus aspirin is superior to treatment with aspirin alone in
suppressing platelet activation after coronary stenting.
(J Am Coll Cardiol 1997;29:1515–9)
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After coronary stent placement, platelet function is a major
determinant of the risk of subacute stent thrombosis (1,2). In
patients treated with coumarin, overlapping heparin and aspi-
rin, we found progressive platelet activation within the first
week after coronary stenting (3). This activation was shown by
increased surface expression of the activated fibrinogen recep-
tor and P-selectin, a marker of alpha-degranulation (3). In
contrast, combined antiplatelet therapy with ticlopidine and
aspirin reduced the surface expression of the activated fibrin-
ogen receptor and prevented further alpha-degranulation after
stenting (3). Consistent with these functional studies, we
showed (4) that combined antiplatelet therapy improves stent
patency compared with anticoagulation.
It is unclear whether the differential effect of the two
antithrombotic regimens is due to the antiplatelet effects of
ticlopidine or is caused by platelet activation through unfrac-
tionated heparin (3–9). No previous study has specifically
addressed the role of ticlopidine in combined antiplatelet
therapy. However, treatment with ticlopidine is costly and can
exert rare but potentially life-threatening side effects, such as
neutropenia (10,11).
In the present randomized study we investigated the con-
tribution of ticlopidine to the inhibition of platelet activation
by combined antiplatelet therapy after coronary stenting.
Methods
Patient selection and study protocol. The study included
patients with successful intracoronary stent placement after
percutaneous transluminal coronary angioplasty (PTCA) at
our institution. Indications for stenting were extensive coro-
nary dissections after PTCA, complete vessel closure, residual
stenosis $30% and lesions in venous bypass grafts. Exclusion
criteria were contraindications for aspirin or ticlopidine, abso-
lute indication for anticoagulation, stents primarily intended as
a bridge to aortocoronary bypass grafting, acute myocardial
infarction and antecedent treatment with ticlopidine.
Immediately after stenting, patients were randomized by
means of sealed envelopes to the ticlopidine group receiving
ticlopidine (Tiklyd, Sanofi-Winthrop), 250 mg twice daily, plus
aspirin (Bayer), 100 mg twice daily, or to the aspirin group
receiving aspirin, 100 mg twice daily, alone. Peripheral venous
blood samples were obtained immediately after completion of
the procedure and daily thereafter until day 5. All patients gave
written informed consent. The study was approved by our
institutional ethics committee.
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Stent procedure and poststenting management of patients.
Stent implantation was performed as previously described
(4,12). Before PTCA, heparin 15,000 U, and aspirin, 500 mg,
were given intravenously. The 7-mm or the articulated 15-mm
standard Palmaz-Schatz stent (Johnson & Johnson) was hand-
crimped on conventional angioplasty balloons. We slightly
oversized the balloons and optimized stent apposition by
higher pressure dilations (.12 atm). If necessary, we im-
planted multiple stents for complete coverage of the dissec-
tion. We did not use intravascular ultrasound but routinely
performed off-line quantitative coronary angiography (AWOS,
Siemens).
After sheath removal and local hemostasis by manual
compression, we applied a pressure bandage for 12 h. Patients
did not receive additional heparin after the intervention, and
the concomitant postinterventional therapy did not differ
between the two treatment groups.
Immunologic detection of platelet activation. Preparation
and immunolabeling of platelets with fluorescein isothiocya-
nate (FITC)–conjugated monoclonal antibodies were per-
formed immediately after blood was drawn, as described
earlier (1,3,13). By use of a fluorescence-activated cell scanner-
Calibur flow cytometer (Becton-Dickinson), the platelet pop-
ulation was identified by size and granularity (.98% positive
for cluster of differentiation [CD]41). Antibody binding of
anti–ligand-induced binding site 1 (LIBS1) and anti-CD62P
was measured as the percent of platelets positive for both
epitopes after subtracting nonspecific fluorescence, deter-
mined by use of an irrelevant isotype-matched FITC-
conjugated immunoglobulin G (Dianova). Anti-CD41 anti-
body binding was determined as the relative change in
fluorescence intensity per platelet. To ensure reproducibility of
flow cytometry, a sample from a healthy control subject was
always analyzed in conjunction with patient samples.
Monoclonal antibodies anti-CD41 and anti-CD62P were
commercially obtained as FITC conjugates (Dianova). Anti-
CD41 is directed against the glycoprotein complex IIb/IIIa
(GPIIb/IIIa) and detects the receptor regardless of whether it
is in its rest or activated form. Anti-LIBS1 monoclonal anti-
body recognizes a cryptic epitope on GPIIIa that becomes
exposed only on the activated and ligand-occupied GPIIb–IIIa
complexes (3). Thus, anti-LIBS1 binding indicates fibrinogen
receptor activity. Anti-CD62P recognizes P-selectin that is
expressed on the activated platelet surface as a consequence of
alpha-degranulation (3).
Statistical analysis. The study primarily sought to test the
hypothesis that by day 5 after stenting, the surface expression
of LIBS1 and P-selectin on platelets differed between the two
treatment groups. This hypothesis was derived from our pre-
vious study comparing combined antiplatelet therapy with
anticoagulation (3). Secondarily, we tested the differences in
LIBS1 and P-selectin surface expression between immediately
after stenting and day 5. We terminated the study prematurely
after the second cardiac event had occurred in the aspirin
group.
Cytometric data that were not normally distributed were
reported as median (interquartile range), and differences were
tested by the Wilcoxon matched-pairs signed-rank or the
Mann-Whitney U test, as appropriate. Otherwise, we report
continuous variables as mean value 6 SD and tested differ-
ences by the t test. Frequencies were tested by the Fisher exact
test. A p value ,0.05 in the two-tailed test was regarded as
significant.
Results
Twenty-five patients were randomized to the aspirin group
and 22 to the ticlopidine group. The two groups were homo-
geneous with respect to major baseline clinical and angio-
graphic characteristics except for a higher number of women
and a slightly larger target vessel diameter in the aspirin group
(Tables 1 and 2). The two groups did not differ significantly
with respect to the prevalence of cardiovascular risk factors or
previous cardiac events (Table 1). Two patients in the aspirin
group sustained subacute stent occlusion on days 4 and 5,
respectively, which was fatal in one. Access site or bleeding
complications were not encountered in either study group.
At the end of the procedure, platelet variables did not show
significant differences between the two treatment groups (Ta-
ble 3). At day 5 after the intervention, the percent of LIBS1-
positive platelets in the ticlopidine group was significantly
lower and the percent of P-selectin–positive platelets tended to
be lower than that in the aspirin group (Table 3, Fig. 1 and 2).
These differences could be attributed to a differential effect of
the two treatment regimens on the time course of the percent
of LIBS1-positive and P-selectin–positive platelets. In the
Abbreviations and Acronyms
CD 5 cluster of differentiation
FITC 5 fluorescein isothiocyanate
GP 5 glycoprotein
LIBS1 5 ligand-induced binding site 1
PTCA 5 percutaneous transluminal coronary angioplasty
Table 1. Baseline Characteristics
Aspirin Group
(n 5 25)
Ticlopidine Group
(n 5 22)
p
Value
Age (yr) 62.1 6 11.4 66.3 6 10.4 0.21
Women 10 (40.0) 1 (4.5) 0.005
Smokers 5 (20.0) 10 (45.5) 0.12
Hypercholesterolemia 2 (7.1) 8 (36.4) 0.08
Arterial hypertension 17 (68.0) 16 (72.7) 0.76
Diabetes mellitus 6 (24.0) 4 (18.2) 0.73
Multivessel disease 14 (46.7) 16 (53.3) 0.38
Previous MI 0 (0) 1 (4.5) 0.47
Previous CABG 1 (4.0) 5 (22.7) 0.08
Previous PTCA 5 (20.0) 3 (13.6) 0.71
Data presented are mean value 6 SD or percent of patients. CABG 5
coronary artery bypass grafting; MI 5 myocardial infarction; PTCA 5 percuta-
neous transluminal coronary angioplasty.
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aspirin group, the percent of LIBS1-positive platelets signifi-
cantly increased between days 1 and 5, whereas there were no
substantial changes in the ticlopidine group (Fig. 1 and 3).
However, the percent of P-selectin–positive platelets did not
change significantly in the aspirin group but decreased signif-
icantly in the ticlopidine group (Fig. 2). Expressed as differ-
ences between days 5 and 1, the changes in the percent of
LIBS1-positive platelets as well as those in P-selectin–positive
platelets differed significantly between the two treatment
groups (p 5 0.002 for LIBS1, p 5 0.014 for P-selectin).
At days 2 to 4, the surface expression of LIBS1 (Fig. 3) and
P-selectin (data not shown) on platelets did not show signifi-
cant differences between the two treatment groups. Platelet
count and anti-CD41 immunofluorescence essentially re-
mained at the same level throughout the study period (Table
3).
The two patients with subacute stent occlusion had elevated
levels of LIBS1 surface expression before the event, represent-
ing the 66th and 87th percentiles of the entire study cohort.
Moreover, their platelet anti-CD41 immunofluorescence
ranged within the highest tercile of the entire study population
(68th and 94th percentiles of the entire study cohort). How-
ever, P-selectin surface expression before stent occlusion cor-
Table 2. Angiographic and Procedural Characteristics
Aspirin
Group
Ticlopidine
Group
p
Value
Target vessel* 0.49
LAD 8 (28.6) 13 (48.3)
LCx 4 (14.3) 4 (13.8)
RCA 14 (50.0) 10 (34.5)
Venous bypass graft 2 (7.1) 2 (6.9)
Indication for stenting* 0.75
Abrupt closure 0 0
Dissection 8 (28.6) 11 (37.9)
Residual stenosis 18 (64.3) 16 (55.2)
Venous bypass graft 2 (7.1) 2 (6.9)
Before PTCA
Ref diam (mm) 3.30 6 0.48 3.00 6 0.48 0.01
MLD (mm) 1.12 6 0.58 0.90 6 0.55 0.18
% diam stenosis 66.9 6 14.8 70.2 6 17.5 0.48
Immediately after stenting
Ref diam (mm) 3.41 6 0.45 3.12 6 0.45 0.02
MLD (mm) 3.08 6 0.51 2.93 6 0.45 0.27
% diam stenosis 9.8 6 12.3 6.2 6 9.5 0.24
Balloon/vessel ratio 1.03 6 0.14 1.08 6 0.14 0.24
No. of 7-mm stent segments/vessel 2.0 6 1.5 2.4 6 1.6 0.32
Length of stented segment (mm) 14.5 6 10.4 16.9 6 11.1 0.41
*Three patients in the aspirin group and seven in the ticlopidine group had
two vessels stented. Data presented are mean value 6 SD or number (%) of
vessels. diam 5 diameter; LAD 5 left anterior descending coronary artery;
LCx 5 left circumflex coronary artery; MLD 5 minimal lumen diameter; RCA
5 right coronary artery; Ref 5 reference.
Table 3. Platelet Counts and Glycoprotein Surface Expression
Aspirin
Group
(n 5 25)
Ticlopidine
Group
(n 5 22)
p
Value
End of stenting procedure
Platelet count (nl21) 191 (176–224) 219 (182–262) 0.28
LIBS1-positive platelets (%) 6.5 (2.9–13.8) 8.0 (4.3–16.7) 0.56
P-selectin–positive platelets (%) 8.5 (5.1–12.9) 8.1 (5.4–16.3) 0.65
Anti-CD41 binding (arb U) 672 (662–703) 685 (649–711) 0.72
Day 5
Platelet count (nl21) 216 (173–277) 222 (192–265) 0.50
LIBS1-positive platelets (%) 18.1 (8.5–35.5) 8.5 (3.1–17.8) 0.025
P-selectin–positive platelets (%) 8.8 (4.0–15.8) 5.8 (3.4–9.5) 0.073
Anti-CD41 binding (arb U) 654 (627–679) 671 (630–704) 0.41
Data presented are median (interquartile range). arb U 5 arbitrary units;
LIBS1 5 ligand-induced binding site 1.
Figure 1. Individual values of surface expression of activated platelet
fibrinogen receptor (LIBS1) immediately after (day 1) and at day 5
after coronary stent placement in patients treated with aspirin and with
aspirin plus ticlopidine. In patients with stent occlusion, the last values
before the event are depicted (18% and 29%).
Figure 2. Individual values of surface expression of P-selectin imme-
diately after (day 1) and at day 5 after coronary stent placement in
patients treated with aspirin and with ticlopidine plus aspirin. In
patients with stent occlusion, the last values before the event are
depicted (6.2% and 8.8%).
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responded to the 47th and 61st percentiles of the entire study
cohort.
Discussion
The present study shows that in suppressing platelet acti-
vation after coronary stenting, combined antiplatelet therapy
with ticlopidine plus aspirin is superior to treatment with
aspirin alone. Ticlopidine plus aspirin, but not aspirin alone,
significantly decreased the surface expression of P-selectin
within 5 days of treatment and prevented the fibrinogen
receptor activation that was found in patients treated with
aspirin alone. By day 5 after stenting, surface expression on
platelets of the activated fibrinogen receptor was significantly
lower in patients treated with than without ticlopidine, and
there was a trend to lower P-selectin surface expression.
The platelet membrane glycoproteins that we analyzed by
flow cytometry are not mere markers of platelet activation but
play important functional roles. P-selectin mediates the inter-
action of platelets with endothelial cells and myeloid leuko-
cytes and signals a variety of inflammatory and procoagulant
responses in these cells (13,14). The GP IIb/IIIa complex
constitutes the central receptor of platelet aggregation and is
the most abundant constitutively expressed protein on the
platelet surface (15). On platelets at rest, GP IIb/IIIa is present
in an inactivated state (15). Stimulation of platelets converts
GP IIb/IIIa to its activated state, which binds fibrinogen (15).
This conversion represents the key mechanisms of platelet
aggregation (15). With the use of anti-LIBS1 antibodies, we
were able to detect this event on circulating platelets in our
patients (2,3). Thus, immunologic characterization of platelet
function enabled us to show that ticlopidine treatment after
stenting interferes with key mechanisms of platelet function.
The importance of the platelet membrane markers that we
examined is further supported by our findings in the two
patients in the aspirin group who had subacute stent occlusion.
Similar to our previous data (1), these patients showed surface
expression of GP IIb/IIIa in the highest tercile of study cohort.
Moreover, the proportions of their platelets circulating with
activated fibrinogen receptors represented the 66th and 87th
percentiles of the study cohort. In concert with our previous
investigations (1,2,4), these findings underscore that the num-
ber and functional status of platelet fibrinogen receptors are of
major pathophysiologic relevance regarding the risk of sub-
acute stent occlusion. Nevertheless, the level of platelet acti-
vation, assessed by immunologic markers, does not suffice to
fully explain subacute stent thrombosis in the two patients in
the aspirin group. This is consistent with the notion that apart
from changes in platelet function, vessel- and procedure-
related mechanisms play a pivotal role in stent thrombosis
(1,12,16–19).
The findings in the ticlopidine group concur with our earlier
study comparing the effect on platelet function of combined
antiplatelet therapy with that of anticoagulation (3). They
suggest that the differential effect of these two antithrombotic
regimens described earlier is predominantly due to the action
of ticlopidine and not to heparin-induced platelet activation.
Blockage of the cyclo-oxygenase pathway by aspirin only
inhibits platelet activation by weak agonists (8). Synergistically
to this effect, ticlopidine interferes with platelet activation by
strong agonists (5). Ticlopidine irreversibly inhibits the binding
of the potent agonist adenosine diphosphate to its receptor on
platelets and thus prevents exposure of fibrinogen receptors
and platelet aggregation (20). Consistent with the known delay
in the onset of action of ticlopidine (5), we were unable to
detect an effect on platelet function before day 5 after stenting.
Moreover, because GP IIb/IIIa is constitutively expressed on
the platelet membrane (15), ticlopidine did not affect the total
number of surface-expressed GP IIb/IIIa complexes, regard-
less of their activation status.
Limitations of the study. After two cardiac events in the
aspirin group, we terminated the study prematurely. This may
have interfered with our ability to detect significant differences
in P-selectin surface expression between the two treatment
groups. Nevertheless, even with a sample size below that
projected, we verified differences in fibrinogen receptor acti-
vation at day 5. Moreover, unequivocal differences in the time
course of P-selectin expression confirmed a differential effect
of the two treatment regimens on this glycoprotein, as well.
Inhomogeneities between the study groups in gender dis-
tribution and target vessel diameter may have had an influence
on the study results. However, we were unable to demonstrate
a relation between gender or target vessel diameter and
platelet markers (data not shown). We therefore have no
reason to assume that these factors had an effect on the
outcome of the study.
Clinical implications. We recently showed (4) that com-
bined antiplatelet therapy is superior to anticoagulation in
preventing stent thrombosis. Our present study suggests that
the beneficial effect of combined antiplatelet therapy can be
attributed to the action of ticlopidine. Withholding ticlopidine
after coronary stenting may thus have deleterious effects. This
implication of our present study is supported by published
Figure 3. Time course of changes in LIBS1 surface expression on
circulating platelets in the ticlopidine and aspirin groups. Median and
interquartile ranges are shown.
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clinical experience. Our present study and two others (21,22)
found an excess of cardiac events when ticlopidine was with-
held after stenting, even though statistical significance was only
reported in one study (22). While this report was in prepara-
tion, results from the Stent Anticoagulation Regimen Study
(STARS) (23) were reported that indicated that combined
antiplatelet therapy with ticlopidine and aspirin more effec-
tively prevents adverse cardiac events after stenting than
therapy with aspirin alone. The platelet function data that we
report strongly support the use of combined antiplatelet
therapy with ticlopidine and aspirin after coronary stenting,
particularly for those patients at high risk for subacute stent
occlusion.
We are grateful to Tanja Breustedt, Caroline Bogner and Ulrike Pfeifer for
excellent technical assistance and Mark Ginsbery, MD, Scripps Clinic, for
providing the anti-LIBS1 monoclonal antibody.
References
1. Neumann FJ, Gawaz M, Ott I, May A, Mo¨ssmer G, Scho¨mig A. Prospective
evaluation of hemostatic predictors of subacute stent thrombosis after
coronary Palmaz-Schatz stenting. J Am Coll Cardiol 1996;27:15–21.
2. Gawaz M, Neumann FJ, Ott I, May A, Ru¨diger S, Scho¨mig A. Changes in
membrane glycoproteins of circulating platelets after coronary stent implan-
tation. Heart 1996;76:166–72.
3. Gawaz M, Neumann FJ, Ott I, May A, Ru¨diger S, Scho¨mig A. Platelet
activation and coronary stent implantation: effect of antithrombotic therapy.
Circulation 1996;94:279–85.
4. Scho¨mig A, Neumann FJ, Kastrati A, et al. A randomized comparison of
antiplatelet with anticoagulant therapy after the placement of coronary
artery stents. N Engl J Med 1996;334:1084–9.
5. Harker LA, Bruno JB. Ticlopidine’s mechanism of action on human
platelets. In: Hass WK, Easton JD, editors. Ticlopidine, Platelets and
Vascular Disease. New York: Springer-Verlag, 1993:41–59.
6. Salzmann EJ, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effects of
heparin and heparin fractions on platelet aggregation. J Clin Invest 1980;65:
65–73.
7. Xiao Z, The´roux P, Plachetka JR. Platelet activation and aggregation by
therapeutic doses of heparin [abstract]. J Am Coll Cardiol 1995;25 Suppl:
117A.
8. Schro¨r K. Antiplatelet drugs: a comparative review. Drugs 1995;50:7–28.
9. Landolfi R, DeCandia E, Rocca B, et al. Effects of unfractionated and low
molecular weight heparins on platelet thromboxane biosynthesis in vivo.
Thromb Haemost 1994;72:942–46.
10. Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing
ticlopidine hydrochloride with aspirin for the prevention of stroke in
high-risk patients. N Engl J Med 1989;321:501–7.
11. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine
Study (CATS) in thromboembolic stroke. Lancet 1989;1:1215–20.
12. Scho¨mig A, Kastrati A, Mudra H, et al. Four-year experience with Palmaz-
Schatz stenting in coronary angioplasty complicated by dissection with
threatened or present vessel closure. Circulation 1994;90:2716–24.
13. Ott I, Neumann FJ, Gawaz M, May A, Schmitt M, Scho¨mig A. Increased
neutrophil-platelet interaction in patients with unstable angina. Circulation
1996;94:1239–46.
14. Neumann FJ, Marx N, Gawaz M, et al. Induction of cytokine expression in
leukocytes by binding of thrombin-stimulated platelets. Circulation 1997;
95:2387–94.
15. Plow EF, Ginsburg MH. Cellular adhesion: GPIIb-IIIa as a prototypic
adhesion receptor. In: Coller BS, editor. Progress in Hemostasis and
Thrombosis. Philadelphia: WB Saunders, 1989:117–56.
16. Schu¨hlen H, Hadamitzky M, Walter H, Vim K, Scho¨mig A. Major benefit
from antiplatelet therapy for patients at high risk for adverse cardiac events
after coronary Palmaz-Schatz stent placement. Circulation 1997;95:2015–21.
17. Foley JB, Brown RI, Penn IM. Thrombosis and restenosis after stenting in
failed angioplasty: comparison with elective stenting. Am Heart J 1994;128:
12–20.
18. Haude M, Erbel R, Issa H, et al. Subacute thrombotic complications after
intracoronary implantation of Palmaz-Schatz stents. Am Heart J 1993;126:
15–22.
19. Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without
anticoagulation accomplished with intravascular ultrasound guidance. Cir-
culation 1995;91:1676–88.
20. Savi P, Laplace MC, Maffrand JP, Herbert JM. Binding of [3H]-2-
methylthio-ATP to rat platelets—effect of clopidogrel and ticolpidine.
J Pharmacol Exp Ther 1994;269:777–2.
21. Hall P, Nakamura S, Maiello L, et al. A randomized comparison of
combined ticlopidine and aspirin therapy versus aspirin therapy alone after
successful intravascular ultrasound-guided stent implantation. Circulation
1996;93:215–22.
22. Goods CM, Al-Shaibi KF, Negus BH, et al. Is ticlopidine a necessary
component of antiplatelet regimens following coronary artery stenting?
[abstract]. J Am Coll Cardiol 1996;27 Suppl 1A:137A.
23. Leon MB, Baim DS, Gordon P, et al. Clinical and angiographic results from
the stent anticoagulation regimen study (STARS) [abstract]. Circulation
1996;94 Suppl I:I-685.
1519JACC Vol. 29, No. 7 NEUMANN ET AL.
June 1997:1515–9 ANTIPLATELET EFFECT OF TICLOPIDINE
